Exsilio Therapeutics is a biotechnology startup focused on developing gene-based therapies that can be administered more than once. The company aims to broaden the reach of gene-based drugs in a scalable and efficient way by leveraging mRNA and lipid nanoparticles to insert new DNA into cells' genomes.
Market
Genetic Medicine
Location
Boston,
MA,
US
Coinvestors
Novartis Venture Fund, Delos Capital, OrbiMed, J.P. Morgan